Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lantheus Holdings (NQ: LNTH )

90.52 +3.20 (+3.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lantheus Holdings

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
NASDAQ:LNTH stands out as a growth opportunity that won't break the bank.
While growth is established for LANTHEUS HOLDINGS INC (NASDAQ:LNTH), the stock's valuation remains reasonable. 
Via Chartmill
Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
From Lantheus Holdings, Inc.
Via GlobeNewswire
Is NASDAQ:LNTH on the Verge of a Major Breakout as a Strong Growth Stock?
Why LANTHEUS HOLDINGS INC (NASDAQ:LNTH) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
NASDAQ:LNTH is showing good growth, while it is not too expensive.
For those who appreciate growth without the sticker shock, NASDAQ:LNTH is worth considering. 
Via Chartmill
Deep Dive Into Lantheus Holdings Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Despite its impressive fundamentals, NASDAQ:LNTH remains undervalued.
LANTHEUS HOLDINGS INC (NASDAQ:LNTH) is an undervalued gem with solid fundamentals. 
Via Chartmill
For those who appreciate value investing, NASDAQ:LNTH is a compelling option with its solid fundamentals.
LANTHEUS HOLDINGS INC (NASDAQ:LNTH): good value for what you're paying. 
Via Chartmill
Lantheus Announces CEO Succession Plan
From Lantheus Holdings, Inc.
Via GlobeNewswire
For those who appreciate value investing, NASDAQ:LNTH is a compelling option with its solid fundamentals.
Don't overlook LANTHEUS HOLDINGS INC (NASDAQ:LNTH)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)
From Lantheus Holdings, Inc.
Via GlobeNewswire
NASDAQ:LNTH—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
LANTHEUS HOLDINGS INC (NASDAQ:LNTH), a strong growth stock, setting up for a breakout. 
Via Chartmill
Unlocking the Growth Potential of NASDAQ:LNTH.
Is LANTHEUS HOLDINGS INC (NASDAQ:LNTH) suited for growth investing? 
Via Chartmill
The Latest Analyst Ratings for Lantheus Holdings
Via Benzinga
Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
From Lantheus Holdings, Inc.
Via GlobeNewswire
Lantheus Reports Preliminary Fiscal Year 2023 Revenue
From Lantheus Holdings, Inc.
Via GlobeNewswire
For those who appreciate growth without the sticker shock, NASDAQ:LNTH is worth considering.
Investors should take note of NASDAQ:LNTH, a growth stock that remains attractively priced. 
Via Chartmill
Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Lantheus Holdings, Inc.
Via GlobeNewswire
NASDAQ:LNTH is showing decent growth, but is still valued reasonably.
LANTHEUS HOLDINGS INC (NASDAQ:LNTH) is showing decent growth, but is still valued reasonably. 
Via Chartmill
New Year, New Gains: The 3 Best AI Stocks to Buy in 2024
These AI stocks offer substantial upside potential compared to the overextended chip players that dominated the theme in 2023. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug
Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic c 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why is Prostate Cancer Focused Lantheus Stock Trading Lower Today?
Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic castration-res 
Via Benzinga
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
From Lantheus Holdings, Inc.
Via GlobeNewswire
Investors should take note of NASDAQ:LNTH, a growth stock that remains attractively priced.
Despite its growth, NASDAQ:LNTH remains within the realm of affordability. 
Via Chartmill
DexCom Stock Earns Healthy Relative Strength Rating Upgrade
In a welcome move, medical device maker DexCom stock saw its Relative Strength Rating rise from 70 to 77 on Tuesday. 
Via Investor's Business Daily
When you look at NASDAQ:LNTH, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
LANTHEUS HOLDINGS INC (NASDAQ:LNTH) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.